Concord Biotech’s niche strengths seen buoying earnings: Analysts

Shares of the Ahmedabad-based biopharma company, which listed a few weeks ago at a more than 20% premium, have notched another 9% gain since then. The shares topped ₹1,000 in intraday trade on Friday, before closing nearly 2% higher on the NSE at ₹983.40.

Generated by Feedzy